Document is current
Any future updates will be listed below
-
Authors
Maestas, Marlie M.
Ishahak, Matthew https://orcid.org/0000-0002-7494-6048
Augsornworawat, Punn https://orcid.org/0000-0001-8602-5433
Veronese-Paniagua, Daniel A.
Maxwell, Kristina G. https://orcid.org/0000-0003-0869-1662
Velazco-Cruz, Leonardo
Marquez, Erica
Sun, Jiameng
Shunkarova, Mira
Gale, Sarah E.
Urano, Fumihiko https://orcid.org/0000-0002-9944-6293
Millman, Jeffrey R. https://orcid.org/0000-0003-0426-3492
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK114233, R01DK127497, R01DK138469, Human Islet Research Network (HIRN) Catalyst Award, T32DK007120, T32DK108742, F31DK125068, R01DK132090, R01DK020579)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
JDRF (3-SRA-2023-1295-S-B)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
WUSTL | Washington University School of Medicine in St. Louis (Rita Levi-Montalcini Postdoctoral Fellowship in Regenerative Medicine)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM139774)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
National Science Foundation (DGE-2139839 and DGE-1745038)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
- License Information
-
More Information
Article History
Received: 25 July 2023
Accepted: 14 June 2024
First Online: 2 July 2024
Competing interests
: P.A., L.V.C., and J.R.M. are inventors of related patents and patent applications. D.A.V.P, L.V.C., and J.R.M. have stock in Sana Biotechnology. M.I. has stock in Vertex Pharmaceuticals. K.G.M. is currently employed by Vertex Pharmaceuticals. L.V.C. and J.R.M. were previously employed by Sana Biotechnology. F.Urano is an inventor of three patents related to the treatment of Wolfram syndrome and diabetes, US 9,891,231 “Soluble MANF in pancreatic beta cell disorders” and US 10,441,574 and US 10,695,324 “Treatment for Wolfram syndrome and other ER stress disorders.” F.Urano is a Founder and President of CURE4WOLFRAM, INC., and Chair of the Scientific Advisory Board for Opris Biotechnologies and Emerald Biotherapeutics. F.Urano receives research funding from Prilenia, and Amylyx pharmaceuticals that are developing novel treatments for neurodegenerative disorders, optic nerve atrophy, diabetes, and Wolfram syndrome. The remaining authors declare no competing interests.
